The STEP trials (NCT03548935, NCT03611582, NCT03548987, and NCT04074161) associated semaglutide, a GLP-1 receptor agonist, with a mean weight reduction of 14.9%–17.4% at week 68 among adults with overweight or obesity without diabetes.31 This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.